<?xml version='1.0' encoding='utf-8'?>
<document id="21048421"><sentence text="[Risk management of QT-prolonging drugs by community pharmacists using a mobile electrocardiograph]." /><sentence text="Prolongation of the QT interval is associated with a high risk of serious arrhythmia, i" /><sentence text="e" /><sentence text=", torsades de pointes (TdP)" /><sentence text=" However, in many cases, the QT-prolonging drug(s) is prescribed without performing a thorough check-up of the patient's condition, especially an electrocardiogram" /><sentence text=" In addition to patient interview, we used an electrocardiogram obtained with a mobile electrocardiograph (RMH-ECG) in a community pharmacy in order to improve the risk management for QT-prolonging drugs" /><sentence text=" A comparison of the results obtained using RMH-ECG (modified I) and 12-lead ECG (I) revealed that both corrected QT (QTc) values were almost identical, and the correlation coefficient was 0" /><sentence text="96" /><sentence text=" In one month, 5 of 948 patients who visited our pharmacy and continuously took QT-prolonging drugs had additional risk factors for TdP (advanced age, female, and drug-drug interaction)" /><sentence text=" We monitored the QT interval of one of these patients" /><sentence text=" She had received erythromycin for 19 months along with other drugs metabolized by a P450 (CYP3A4); benidipine and prednisolone (for over 2 years), and tacrolimus (for 13 weeks)"><entity charOffset="18-30" id="DDI-PubMed.21048421.s11.e0" text="erythromycin" /><entity charOffset="100-110" id="DDI-PubMed.21048421.s11.e1" text="benidipine" /><entity charOffset="115-127" id="DDI-PubMed.21048421.s11.e2" text="prednisolone" /><entity charOffset="152-162" id="DDI-PubMed.21048421.s11.e3" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.21048421.s11.e0" e2="DDI-PubMed.21048421.s11.e0" /><pair ddi="false" e1="DDI-PubMed.21048421.s11.e0" e2="DDI-PubMed.21048421.s11.e1" /><pair ddi="false" e1="DDI-PubMed.21048421.s11.e0" e2="DDI-PubMed.21048421.s11.e2" /><pair ddi="false" e1="DDI-PubMed.21048421.s11.e0" e2="DDI-PubMed.21048421.s11.e3" /><pair ddi="false" e1="DDI-PubMed.21048421.s11.e1" e2="DDI-PubMed.21048421.s11.e1" /><pair ddi="false" e1="DDI-PubMed.21048421.s11.e1" e2="DDI-PubMed.21048421.s11.e2" /><pair ddi="false" e1="DDI-PubMed.21048421.s11.e1" e2="DDI-PubMed.21048421.s11.e3" /><pair ddi="false" e1="DDI-PubMed.21048421.s11.e2" e2="DDI-PubMed.21048421.s11.e2" /><pair ddi="false" e1="DDI-PubMed.21048421.s11.e2" e2="DDI-PubMed.21048421.s11.e3" /></sentence><sentence text=" Three RMH-ECG tests at every 2 weeks revealed that QTcs were normal (0" /><sentence text="43-0" /><sentence text="45 s); therefore, we dispensed drugs without any change in the prescription" /><sentence text=" Approximately 1 in 1200 individuals has a prolonged QT interval without any subjective symptoms, and the time window of drug-induced TdP is considered to be from several hours to months after taking these drugs" /><sentence text=" Therefore, we think that an ECG test should be performed in community pharmacies before dispensing QT-prolonging drugs and that the QT interval should be monitored" /><sentence text="" /></document>